YORK, Pa., Nov. 22, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) today announced that all of the proposed items for its 2013 Annual General Meeting of stockholders were approved by the Company's shareholders.
The Company also announced changes to the Board of Directors and management team, including the appointment of Alan Shortall to Chairman of the Board of Directors, following Slavko James Joseph (Jim) Bosnjak's decision to step down from the position for both personal and professional reasons. Mr. Bosnjak will remain on the Board as Deputy Chairman and Lead Independent Director. Mr. Shortall will retain his role as CEO of Unilife. Dr. Ramin Mojdeh was appointed President of the Company, and will retain his position as Chief Operating Officer.
The Company has posted a complete audio archive of the meeting, along with the slide show presentation from Unilife CEO Mr. Alan Shortall focusing on the Company's commercial pipeline on its website at http://ir.unilife.com/events.cfm.
"I have tirelessly worked with Jim to accomplish great things for Unilife. And I speak for everyone at the Company, including the other members of the Board, when saying that we are lucky to have convinced Jim to remain with us as Deputy Chairman," said Mr. Shortall. "I would also like to thank the members of the board of directors for their confidence and appointing me Chairman. I believe that being Chairman and CEO will have some clear, near-term benefits in the negotiation of contracts."
"I would like to congratulate Ramin on his appointment to President. He has been a driving force behind our rapid ascent to the top of the drug delivery systems business and his work ethic, experience and leadership have been instrumental in our success at the negotiating table," continued Mr. Shortall.
"Over the coming months, we will continue to build upon our accomplishments and sign additional contracts with a series of pharmaceutical customers that will capture more market share for Unilife. We expect most of these will include upfront cash and recurring payments. Moving forward, we expect sequential quarterly growth in fiscal year 2014, and significant annual growth year over prior year for fiscal year 2014 and beyond."
About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, intraocular delivery systems and novel devices. Each of these innovative, differentiated technology platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.
Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.
General: UNIS-G
|
Investor / PR Contacts (US):
|
Analyst Enquiries
|
Investor Contacts (Australia)
|
|
|
Todd Fromer / Garth Russell
|
Lynn Pieper
|
Jeff Carter
|
|
|
KCSA Strategic Communications
|
Westwicke Partners
|
Unilife Corporation
|
|
|
P: + 1 212-682-6300
|
P: + 1 415-202-5678
|
P: + 61 2 8346 6500
|
|
SOURCE Unilife Corporation